Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation Following Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial

Peter R. Kowey, MD,1 Paul Dorian, MD,2 L. Brent Mitchell, MD,3 Craig M. Pratt, MD,4 Denis Roy, MD,5 Peter J. Schwartz, MD,6 Jerzy Sadowski, MD, PhD,7 Dorota Sobczyk, MD,7 Andrzej Bochenek, MD, PhD,8 Egon Toft, MD,9 for the Atrial arrhythmia Conversion Trial (ACT-II) Investigators*

From the 1Division of Cardiovascular Disease, Lankenau Hospital and Institute of Medical Research, Wynnewood, Pennsylvania, 2Division of Cardiology, St. Michael’s Hospital and University of Toronto, Toronto, Ontario, Canada, 3Libin Cardiovascular Institute of Alberta, Calgary Health Region and University of Calgary, Calgary, Alberta, Canada, 4Baylor College of Medicine and The Methodist Hospital, Houston, Texas, 5Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Quebec, Canada, 6Department of Cardiology, University of Pavia, and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 7Cardiovascular Surgery and Transplantology Department, Jagiellonian University, Krakow, Poland, 8First Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland, 9Department of Health Science and Technology, Aalborg University and Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark

*ACT-II Investigators are listed in the Appendix.

Address correspondence to
Peter R. Kowey, MD, Lankenau Medical Office Building East, 100 Lancaster Ave, Suite 556, Wynnewood, PA 19096
Tel: 610-649-6980
Fax: 610-649-6990
Email: KoweyPR@MLHHeart.org

Short title: Vernakalant in Post-Cardiac Surgery Arrhythmia

ABSTRACT

Background—Postoperative atrial arrhythmias are common and are associated with considerable morbidity. This study was designed to evaluate the efficacy and safety of vernakalant for the conversion of atrial fibrillation (AF) or atrial flutter (AFL) following cardiac surgery.

Methods and Results—This was a prospective, randomized, double-blind, placebo-controlled trial of vernakalant for the conversion of AF or AFL following coronary artery bypass graft, valvular surgery, or both. Patients were randomized 2:1 to receive a 10-minute infusion of vernakalant 3 mg/kg or placebo. If AF or AFL was present after a 15-minute observation period, then a second 10-minute infusion of vernakalant 2 mg/kg or placebo was given. The primary endpoint was the conversion of post-cardiac surgery AF or AFL to sinus rhythm (SR) within 90 minutes of dosing. In patients with AF, 47 of 100 (47%) patients who received vernakalant converted to SR compared with 7 of 50 (14%) patients who received placebo (P<.001). The median time to conversion was 12 minutes. Vernakalant was not effective in converting postoperative AFL to SR. Two serious adverse events occurred within 24 hours of vernakalant administration (hypotension and complete atrioventricular block). There were no cases of torsades de pointes, sustained ventricular tachycardia, or ventricular fibrillation. There were no deaths.

Conclusions—Vernakalant was safe and effective in the rapid conversion of AF to SR in patients who developed AF post-cardiac surgery.

Clinical Trial Registration


Key Words: atrial fibrillation, cardiac surgery, antiarrhythmic drugs
Atrial arrhythmias occur following coronary artery bypass graft (CABG) and valvular surgery in approximately 20% to 50% of patients, depending on definitions, types of surgery, and surveillance methods.1-3 Atrial fibrillation (AF) is the most common atrial arrhythmia in this setting.4-6 Postoperative atrial arrhythmias are associated with increased morbidity from stroke, congestive heart failure, hemodynamic compromise, and ventricular dysrhythmias, and with prolonged hospitalization and increased costs and rates of rehospitalization following discharge.1,7-10

Current treatment strategies for post-cardiac surgery AF are similar to those for acute AF, and consist of thrombosis prevention and various agents to control ventricular response rate and restore sinus rhythm (SR).2,11-13 Currently available antiarrhythmic drugs have variable efficacy and safety profiles and may produce significant cardiac and noncardiac adverse effects. They may be contraindicated in some postoperative patients because of their negative inotropic or chronotropic effects.11,14 A safe and effective agent for the rapid conversion of atrial arrhythmias to SR would benefit post-cardiac surgery patients.

Vernakalant hydrochloride injection (RSD1235) is a novel, relatively atrial-selective antiarrhythmic agent for the conversion of AF to SR that acts by means of frequency-dependent blockade of Na⁺ channels as well as blockade of early-activating K⁺ channels.15 In a placebo-controlled phase 2 trial (n=56), vernakalant rapidly converted recent-onset AF (lasting 3–72 hours) to SR.16 In addition, 2 recent placebo-controlled, phase 3 clinical studies have confirmed the efficacy and safety of vernakalant in converting recent-onset AF (lasting 3 hours–7 days) to SR.17,18 The rate of conversion of AF to atrial flutter (AFL) in these nonsurgical populations was
low (5.6% and 8.6% in the phase 2 and 3 trials, respectively). This study evaluated the efficacy of vernakalant in converting AF or AFL to SR in patients recovering from CABG, valvular surgery, or both.

METHODS

Study Design

This was a phase 3, prospective, randomized, double-blind, placebo-controlled study conducted at 43 sites in Canada, the United States, Denmark, Italy, Poland, Argentina, and India. The study was approved by an institutional review board at each site and all patients gave written informed consent.

Randomization codes were generated by an unblinded statistician who was not involved in the study operations. The unblinded pharmacist or designee at each site randomized eligible patients by calling a central randomization center. All of the study staff, with the exception of the site pharmacist, were blinded to the identity of the treatment assignments. The pharmacist at each site prepared study drug or placebo as required and ensured that the volume of study treatment and the time for delivery to study personnel was equivalent, regardless of treatment assignment.

Eligible patients included men and women ≥18 years of age, with sustained AF or AFL (lasting 3–72 hours) occurring between 24 hours and 7 days after CABG, valvular surgery, or both. Patients were hemodynamically stable (systolic blood pressure [SBP] >90 mm Hg and <160 mm Hg and diastolic blood pressure <95 mm Hg), weighed 45 to 136 kg (99–300 lb), and had documented SR before and after surgery. Women were not pregnant or nursing, and, if premenopausal,
were using an effective form of birth control. Patients were excluded if they had an uncorrected QT interval >500 ms; a ventricular response rate to AF <45 bpm; a QRS interval >140 ms without a pacemaker; second- or third-degree atrioventricular (AV) block; a history of torsades de pointes; unstable class IV congestive heart failure; serious hepatic or renal disease; end-stage disease states; a reversible cause of AF such as hyperthyroidism or pulmonary embolism; an uncorrected electrolyte imbalance; digoxin toxicity; or had received another investigational drug or intravenous vernakalant in the 30 days before enrollment. Patients were excluded if oral amiodarone had been taken in the previous 3 months, if intravenous amiodarone had been administered in the previous 24 hours, or if class I or class III antiarrhythmic drugs had been administered after cardiac surgery. Treatment with rate control drugs, such as β-adrenergic blocking agents, calcium antagonists, or digoxin, was permitted provided heart rate (HR) was >50 bpm and that a loading dose or bolus supplementation of the agent was not given in the 2 hours before study drug administration.

Patients were randomized 2:1 to receive either a 10-minute infusion of vernakalant 3.0 mg/kg or placebo (normal saline solution), followed by a 15-minute observation period. If the patient did not demonstrate conversion to SR, a second 10-minute infusion of vernakalant 2.0 mg/kg or placebo was administered. The infusion was discontinued if any of the following were observed: uncorrected QT interval ≥550 ms or prolongation of the uncorrected QT interval >25%, HR <45 bpm lasting ≥30 seconds with symptoms or <40 bpm lasting ≥30 seconds with or without symptoms, SBP >190 mm Hg or <85 mm Hg or new requirement for inotrope
support, new bundle branch block or QRS interval prolongation of ≥50%, any polymorphic ventricular tachycardia, sinus pause of ≥5 seconds, change in cardiac rhythm or AV conduction that compromised patients’ safety, or any intolerable side effects. Electrical cardioversion and the administration of any additional antiarrhythmic medication were withheld for at least 2 hours following dosing.

Patients were monitored at the study facility for a minimum of 24 hours postdosing. Electrocardiograms (ECGs) were recorded and vital signs were measured at specified intervals during the screening period, the subsequent 24 hours, upon conversion to SR, at the follow-up visit scheduled at discharge (up to day 14), and at the occurrence of a serious adverse event (AE). Telemetry was performed prior to treatment and continuously thereafter for at least 2 hours postdose, and Holter monitoring commenced at baseline and continued for 24 hours postdose. AEs were recorded through the follow-up visit, and serious AEs were recorded throughout the study period, which concluded with a telephone follow-up on day 30.

Study Endpoints

The prespecified primary efficacy endpoint was the proportion of patients with AF/AFL following CABG, valvular surgery, or both who demonstrated conversion to SR, for a minimum duration of 1 minute, within 90 minutes of first infusion. Patients reaching this endpoint were categorized as responders. The secondary efficacy endpoints were the time to conversion of AF/AFL to SR among responders, the
proportion of responders with AF and their time to conversion, and the proportion of patients with AFL who responded to treatment and their time to conversion.

Exploratory analyses included the proportion of all responders who required a single dose of study drug to demonstrate conversion, the proportion of responders who remained in SR at hour 24 and day 7, the proportion of patients with at least 1 arrhythmia symptom at each scheduled assessment and the proportion of patients who reported each symptom at each assessment, and the influence of baseline and demographic characteristics, including type of surgery, on the primary endpoint.

All 12-lead ECG recordings were sent to a central ECG laboratory for analysis and interpretation. All 12-lead ECGs and Holter monitor recordings were reviewed by members of a Clinical Events Committee, who were blinded to treatment, to determine the baseline arrhythmia and to assess conversion to SR. Safety was monitored by a Data Safety and Monitoring Board.

Statistical Analysis

All statistical tests were 2-sided and conducted at the .05 significance level. All patients in each treatment group who received any amount of study drug were analyzed for efficacy and safety.

It was anticipated that a total of approximately 210 subjects would be randomized (140 to vernakalant and 70 to placebo) in this clinical trial. Assuming a spontaneous conversion rate of 15%, this would provide 178 evaluable patients. Assuming a placebo response rate of 35%, the proposed sample size would provide 84% power to detect a minimum difference between placebo and vernakalant of
23.5% (i.e., a vernakalant response rate of 58.5%). This was based on a two-sided chi-square test with a 5% significance level.

Demographics and baseline characteristics were compared using a 1-way analysis of variance with a fixed effect for treatment for continuous variables and a Fisher exact test for categorical variables. The primary endpoint analysis was based on the Cochran-Mantel-Haenszel test stratified by country. Logistic regression was used to investigate the effect of various baseline and demographic characteristics on the primary endpoint. For the secondary endpoints, the Kaplan-Meier method was used to summarize the time to conversion and the log-rank test was used to compare the distributions. Comparisons of the proportion variables for the secondary endpoints were conducted using the same methods as used for the primary endpoint. The Kaplan-Meier method was used to determine the proportion of patients who remained in SR at hour 24 and day 7. A Fisher exact test was used to summarize and compare the proportion of patients reporting AF/AFL symptoms at various time points. Analysis of ECG intervals at each time point was based on an analysis of covariance with treatment as a factor and baseline as a covariate. The p-values reported are raw unadjusted p-values, which do not account for multiplicity.

RESULTS

Study Population

From June 2004 to February 2007, a total of 190 patients were randomized to either vernakalant or placebo (Figure 1). Twenty-nine patients did not receive study drug, including 24 patients (7 placebo and 17 vernakalant) who spontaneously converted
to SR prior to treatment. Of the other 5 patients, 2 patients assigned to vernakalant withdrew consent and 3 patients (1 vernakalant and 2 placebo) violated inclusion or exclusion criteria. Accordingly, 161 patients (54 placebo and 107 vernakalant) received treatment and were included in the efficacy and safety analyses. Of the 161 patients treated, 150 had AF and 10 had AFL at randomization. One patient who was assigned to the vernakalant group, was later adjudged by the Clinical Events Committee to be in SR prior to and after treatment.

The 2 treatment groups did not differ significantly in baseline demographic or clinical characteristics (Table 1). Among patients in whom left ventricular ejection fraction (LVEF) was known, the majority in both groups had a normal LVEF. Most patients had undergone CABG surgery.

Efficacy

The primary endpoint, conversion of AF/AFL to SR for a minimum duration of 1 minute within 90 minutes of first infusion, was achieved in 44.9% (48 of 107) and 14.8% (8 of 54) of patients given vernakalant and placebo, respectively ($P<.001$) (Figure 2). In patients with AF at baseline, 47% (47 of 100) of patients given vernakalant demonstrated conversion to SR, while only 14% (7 of 50) of patients given placebo did so ($P<.001$). Of the patients with AFL at baseline, none of the 6 given vernakalant and 1 of the 4 given placebo demonstrated conversion to SR.

Prespecified subgroup analyses by surgery type revealed no significant differences in responder rates between patients who underwent CABG surgery and those who underwent valvular surgery (Table 2). There was a significant difference
in responder rates between vernakalant and placebo in patients who underwent CABG surgery alone (34/71 [47.9%] vs 5/37 [13.5%], \( P=.002 \)). There was no effect of age, gender, LVEF, or left atrial diastolic dimension on the probability of conversion to SR. Patients given vernakalant who received rate-control medications, however, were more likely to demonstrate conversion to SR than were patients who did not receive rate-control medications (22/41 [53.7%] vs 26/66 [39.4%], \( P=.027 \)).

AF-to-SR conversion with vernakalant was rapid, with a 12.4-minute median time to conversion (Figure 3). Among patients with AF/AFL who responded to treatment with vernakalant, the median time to conversion was 12.3 minutes (range, 0.5–57.1 min). In addition, most patients (75%) who responded to vernakalant demonstrated conversion to SR with a single dose of vernakalant. Excluding those with missing data, 60% of the 48 patients with AF/AFL who responded to vernakalant were in SR at 24 hours and 57% were in SR at day 7; only 3 responders who reverted back to AF or AFL did so within 2 hours.

Regarding AF/AFL symptoms at minute 90, significantly fewer patients given vernakalant compared with placebo experienced rapid heartbeats (15.9% vs 46.3%, respectively, \( P<.001 \)), palpitations (16.8% vs 44.4%, \( P<.001 \)), and irregular pulse (22.4% vs 42.6%, \( P=.01 \)). These results are consistent with the greater proportion of patients who received vernakalant that were in SR at minute 90.

Safety
Serious AEs were reported for 9.3% (10 of 107) and 11.1% (6 of 54) of patients given vernakalant and placebo, respectively. Within 24 hours of dosing, 2 serious AEs occurred in patients who received vernakalant (and were considered drug related) and none occurred in patients given placebo. One patient who demonstrated conversion to SR developed hypotension (arterial blood pressure of 49/39 mm Hg) 3 minutes after receiving 1 partial dose of vernakalant. This patient was treated with intravenous fluids and norepinephrine, and the event resolved 3 minutes later. Another patient experienced complete AV block (following conversion) during the first infusion of vernakalant. External pacing through an epicardial wire (placed at the time of surgery) was initiated and the patient recovered 12 minutes later. There were no deaths reported in this study.

Treatment-emergent AEs occurring within 24 hours of study drug administration occurred in 38.3% (41 of 107) and 31.5% (17 of 54) of patients who received vernakalant or placebo, respectively. Of these, the most common events were AF (vernakalant: 8.4%; placebo: 9.3%) and nausea (vernakalant: 5.6%; placebo: 3.7%). Three patients in the vernakalant group (and none in the placebo group) discontinued study drug, one each due to hypotension (described above), complete AV block (described above), and right bundle branch block.

Unsurprisingly, in this population a small proportion of AF patients in both groups experienced AFL; among patients with AF, 5 given vernakalant (5%) and 2 given placebo (4%) demonstrated conversion to AFL, all within 1 hour of infusion. Two of the patients given vernakalant and 1 given placebo later converted to SR.
In the first 2 hours and 24 hours after the start of dosing, the incidence of all ventricular arrhythmia events was similar in both treatment groups (Table 3), including 4 patients given vernakalant who developed unsustained ventricular tachycardia in the first 2 hours, lasting 3-12 beats. The unsustained polymorphic ventricular tachycardias did not resemble torsades de pointes morphologically. In addition, there were no marked increases in QT interval or typical variations in RR interval (pause-dependent sequences) during the arrhythmia initiation to suggest torsades de pointes. These arrhythmias were identified by Holter monitoring and 12-lead ECG data and none were reported as AEs. Over the same observation periods, bradycardia events occurred more often in the vernakalant group (Table 3). Few patients had an HR <40 bpm, and the incidence of an HR <40 bpm was similar among the vernakalant and placebo groups. Although the incidence of hypotension events was similar among treatment groups, more patients given vernakalant had a SBP <90 mm Hg. There were no cases of torsades de pointes, sustained ventricular tachycardia, or ventricular fibrillation in either treatment group.

**Vernakalant and ECG Parameters**

The mean±SD HR among all patients given vernakalant fell from 122±26 bpm at baseline to 105±23 bpm 10 minutes after initiation of treatment. This was largely accounted for by the reduction in HR among patients who demonstrated conversion to SR (Figure 4A). Among those given vernakalant who remained in AF or AFL, the decrease in HR, while significantly different from placebo through minute 50 and remaining essentially the same through hour 2, was smaller (Figure 4A). In patients
who demonstrated conversion to SR with vernakalant, from baseline to the end of
the first infusion, the mean QRS interval increased from 101.0±14.9 to 106.6±16.1,
and the mean Fridericia-corrected QT interval (QTcF) increased from 407.3±25.1 to
426.0±30.4 ms. The mean Bazett-corrected QT interval (QTcB) decreased from
454.6±27.3 ms to 445.6±34.8 ms.

To avoid the potential confounding effects on QRS and QT intervals due to
reductions in HR following conversion to SR, the effects of vernakalant on ECG
parameters were also compared with placebo in patients who remained in AF or
AFL. Among nonresponders, vernakalant prolonged QRS intervals from a baseline
value of 99.7±12.2 ms to a peak of 110.0±22.2 ms at the end of second infusion.
Increases from baseline in QRS intervals were significantly greater with vernakalant
than with placebo at all times from 10 minutes to 2 hours (Figure 4B). Maximum
increases from baseline in mean QTcB and QTcF with vernakalant in patients who
remained in AF/AFL occurred at the end of first infusion, and these increases were
significantly greater with vernakalant than with placebo from minutes 10 to 50
(Figures 4C and D). The minute-90 QTcF difference from baseline was also
significant.

Among the 93 patients given vernakalant and 44 given placebo, with QT
measurements taken at baseline and at 10 minutes, 28% and 7%, respectively, had
a QTcB >500 ms at the end of first infusion. If patients with baseline QTcB >500 ms
are excluded, these percentages fall to 24% with vernakalant and 2% with placebo.
Within 90 minutes, the percentage of patients with a QTcB >500 ms in the 2 treatment
groups was similar (7% vernakalant vs 10% placebo for all patients; 4% and 8%,

CIRCULATIONAHA/2009/870204/R14
respectively, for patients with baseline QTcB ≤500 ms). For QTcF, 3% of patients given vernakalant and none of the patients given placebo had values >500 ms at the end of first infusion, all of whom had baseline values ≤500 ms. Within 90 minutes, none of the patients in either treatment group had QTcF >500 ms.

DISCUSSION

After cardiac surgery, postoperative AF is still common despite use of β-blockers and other measures of prophylaxis, and it often develops in patients with comorbidities predisposing to prolonged hospitalization. The incidence of postoperative AF is also rising, possibly due to the increasing age of cardiac surgical patients. According to recent guidelines for AF management, it is reasonable to restore SR in patients who develop AF following cardiac surgery (Level of evidence: B) with pharmacological treatments, which are more commonly used than electrical cardioversion. Moreover, several studies have demonstrated an increased risk of stroke in post-CABG patients. Therefore, anticoagulation is appropriate when AF persists 48 hours or longer. Anticoagulation after cardiac surgery can also be hazardous, making prompt restoration of SR all the more reasonable.

Despite the prevalence and importance of AF secondary to cardiac surgery, few randomized, placebo-controlled studies have evaluated the efficacy of antiarrhythmic agents for restoring SR in post-cardiac surgery patients. Ibutilide was shown to be more effective than placebo in converting post-cardiac surgery AF or AFL to SR; in that study, however, polymorphic ventricular tachycardia, both sustained and nonsustained, was reported in approximately 2% of patients, which
has limited its usefulness. Amiodarone is frequently used intravenously, but evidence to support its efficacy for this indication is scarce. Furthermore, clinicians may be reluctant to use electrical cardioversion because of the mandate for anesthesia.

Nevertheless, it is deemed advisable by guidelines to restore SR in patients with postoperative AF that is complicated by significant symptoms, hemodynamic instability, or a contraindication to anticoagulant therapy. In all cases, the choice of drug should be based on individual patient characteristics.

In the present study, vernakalant was significantly more effective in rapidly converting AF to SR in patients with sustained AF that began 24 hours to 7 days after CABG, valvular surgery, or both. Treatment-associated conversion was demonstrated in 47% of vernakalant and 14% of placebo patients. AF to SR conversion with vernakalant was rapid, with a median time to conversion of 12 minutes, and 75% of responders required only 1 dose of vernakalant. Significantly fewer patients given vernakalant experienced rapid heartbeats, palpitations, and irregular pulse rates compared with those given placebo. In 6 patients with AFL at baseline, vernakalant did not convert the arrhythmia to SR. While there were too few patients with AFL to draw any firm conclusions in the postoperative population, vernakalant has not proven effective in converting AFL to SR in any study to date. Effectiveness for AFL conversion may require more potent Ikr block, as with ibutilide. There were no significant differences in treatment-associated conversion rates among those who underwent CABG or valvular surgery alone, although the number of valvular surgery patients was small.
Patients given vernakalant who remained in AF or AFL had significant increases in QRS, QTcB, and QTcF intervals, with the latter 2 returning to placebo levels within 2 hours. In those who remained in AF or AFL, vernakalant also had a small, but significant, HR-lowering effect, which dissipated within 90 minutes. These observations are likely caused by K⁺ channel blockade (which occurs predominantly in the atria but also affects the ventricles), Na⁺ channel blockade, and modest AV-nodal–blocking effects of vernakalant. Patients given vernakalant did experience a higher incidence of bradycardia events, but this is likely related to the high rate of SR conversion with vernakalant and the subsequent large drop in HR.

Vernakalant was well tolerated. Only 2 patients in the vernakalant group discontinued due to serious AEs within 24 hours of treatment; each patient recovered without sequelae. One of these patients developed hypotension during the initial vernakalant infusion. The infusion was discontinued; saline and norepinephrine were given and the event resolved 3 minutes after onset. Hypotension with vernakalant infusion typically occurs during or immediately following the infusion, is generally transient, and responds to saline. A similar incidence of ventricular arrhythmia events was reported in the placebo and vernakalant groups in the 24 hours after dosing, and there were no cases of sustained ventricular tachycardia, torsades de pointes, or ventricular fibrillation in either group.

The primary limitation of this study is the population sizes. The total population and the CABG surgery population (67% of the total) were sufficient for the overall analysis and the CABG subgroup analysis. However, too few patients
had valvular surgery or both CABG and valvular surgery, so the effect of vernakalant in those subgroups is not entirely clear. Further study of vernakalant in these situations is warranted. In conclusion, similar to findings from earlier phase 3 trials in patients with AF in other settings,\textsuperscript{17,18} this study demonstrated that vernakalant was safe and effective for AF-to-SR cardioversion in post-cardiac surgery patients.

**ACKNOWLEDGMENTS**
The authors thank the nurse coordinators at the participating sites for their collaboration in this study, the scientific teams at Cardiome Pharma Corp., including Gregory Beatch, Garth Dickinson, Sheila Grant, Heather Kato, and Brian Mangal, and at Astellas Pharma US, Inc., including Therese Kitt. The authors also thank David S. Berger and Kara L. Guarini from JL Shapiro Associates Inc for assistance in preparing the manuscript. The content of this paper, however, is solely the responsibility of the authors.

**FUNDING SOURCES**
This study was sponsored by Astellas Pharma US, Inc, Deerfield, Ill, and Cardiome Pharma Corp., Vancouver, British Columbia, Canada.

**DISCLOSURES**
Peter R. Kowey has received consultant fees from Cardiome Pharma Corp. and Astellas Pharma US, Inc. Paul Dorian and L. Brent Mitchell have received consultant fees from Cardiome Pharma Corp. Craig M. Pratt has received consultant fees from Cardiome Pharma Corp. and Astellas Pharma US, Inc. Denis Roy has received consultant fees from Cardiome Pharma Corp. and Astellas Pharma US, Inc., and is a member of the scientific advisory board for Cardiome Pharma Corp. Peter J. Schwartz and Egon Toft have received consultant fees from Cardiome Pharma Corp. Jerzy Sadowski, Dorota Sobczyk, and Andrzej Bochenek have nothing to disclose.
APPENDIX

List of Committees, Centers, and Investigators

Data Safety Monitoring Board—J. Camm, D. DeMets, L. Køber, J.Y. Le Heuzey, A. Waldo;
REFERENCES


Table 1. Baseline Demographic and Clinical Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Treatment Group</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n=54)</td>
<td></td>
<td>Vernakalant (n=107)</td>
</tr>
<tr>
<td>Men, no. (%)</td>
<td>40 (74.1)</td>
<td>81 (75.7)</td>
<td></td>
</tr>
<tr>
<td>Caucasian, no. (%)</td>
<td>50 (92.6)</td>
<td>101 (94.4)</td>
<td></td>
</tr>
<tr>
<td>Age, y (mean±SD)</td>
<td>67.8±6.4</td>
<td>68.3±7.7</td>
<td></td>
</tr>
<tr>
<td>Surgery type, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG</td>
<td>37 (68.5)</td>
<td>71 (66.4)</td>
<td></td>
</tr>
<tr>
<td>Valvular</td>
<td>10 (18.5)</td>
<td>28 (26.2)</td>
<td></td>
</tr>
<tr>
<td>Both</td>
<td>7 (13.0)</td>
<td>8 (7.5)</td>
<td></td>
</tr>
<tr>
<td>Left atrial and ventricular measurements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF &lt;50%,* no. (%)</td>
<td>12 (30.8)</td>
<td>31 (36.0)</td>
<td></td>
</tr>
<tr>
<td>Left atrial diastolic dimension, mm (mean±SD)</td>
<td>42.9±6.8</td>
<td>42.0±6.6</td>
<td></td>
</tr>
<tr>
<td>Arrhythmia, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AF</td>
<td>50 (92.6)</td>
<td>100 (93.5)</td>
<td></td>
</tr>
<tr>
<td>AFL</td>
<td>4 (7.4)</td>
<td>6 (5.6)</td>
<td></td>
</tr>
<tr>
<td>History of significant medical conditions, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension‡</td>
<td>40 (74.1)</td>
<td>72 (67.3)</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease‡</td>
<td>45 (83.3)</td>
<td>84 (78.5)</td>
<td></td>
</tr>
<tr>
<td>Heart failure‡</td>
<td>15 (27.8)</td>
<td>36 (33.6)</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Baseline Demographic and Clinical Characteristics (cont’d)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Treatment Group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n=54)</td>
</tr>
<tr>
<td>Concomitant therapy, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Any rate control</td>
<td>38 (70.4)</td>
</tr>
<tr>
<td>β-blockers</td>
<td>38 (70.4)</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>3 (5.6)</td>
</tr>
<tr>
<td>Digitalis glycosides</td>
<td>3 (5.6)</td>
</tr>
<tr>
<td>Any rhythm control</td>
<td></td>
</tr>
<tr>
<td>Class I antiarrhythmics§</td>
<td>0</td>
</tr>
<tr>
<td>Class III antiarrhythmics‖</td>
<td>3 (5.6)</td>
</tr>
</tbody>
</table>

CABG=coronary artery bypass graft; LVEF=left ventricular ejection fraction; AF=atrial fibrillation; AFL=atrial flutter.

*Among patients in whom LVEF was known.
†One patient given vernakalant was adjudged by the Clinical Events Committee to be in sinus rhythm prior to and after treatment.
‡Derived from verbatim terms in medical history after study database was locked and unblinded.
§Class I antiarrhythmics included disopyramide, flecainide, procainamide, propafenone, and quinidine.
‖Class III antiarrhythmics included amiodarone, dofetilide, ibutilide, and sotalol.
Table 2. Treatment-Associated Conversion of AF/AFL to SR by Surgery Type

<table>
<thead>
<tr>
<th>Surgery Type</th>
<th>Placebo</th>
<th>Vernakalant</th>
<th>(Vernakalant/Placebo)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CABG</td>
<td>5/37 (13.5%)</td>
<td>34/71 (47.9%)</td>
<td>34.4% (18.4%–50.4%)</td>
<td>.002</td>
</tr>
<tr>
<td>Valvular</td>
<td>2/10 (20.0%)</td>
<td>10/28 (35.7%)</td>
<td>15.7% (−14.8% to 46.2%)</td>
<td>.562</td>
</tr>
<tr>
<td>CABG and valvular</td>
<td>1/7 (14.3%)</td>
<td>4/8 (50.0%)</td>
<td>35.7% (−7.6% to 79.0%)</td>
<td>.088</td>
</tr>
</tbody>
</table>

AF=atrial fibrillation; AFL=atrial flutter; SR=sinus rhythm; CI=confidence interval; CABG=coronary artery bypass graft.
### Table 3. Ventricular Arrhythmia Events, Bradycardia Events, and Hypotension Events in the First 24 Hours

<table>
<thead>
<tr>
<th>Event, no. (%)</th>
<th>0 to 2 Hours (n=54)</th>
<th>0 to 24 Hours (n=54)</th>
<th>2 to 24 Hours (n=107)</th>
<th>0 to 24 Hours (n=107)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any ventricular arrhythmia event*</td>
<td>2 (3.7)</td>
<td>7 (13.0)</td>
<td>5 (4.7)</td>
<td>16 (15.0)</td>
</tr>
<tr>
<td>Torsades de pointes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ventricular tachycardia †</td>
<td>0</td>
<td>7 (13.0)</td>
<td>4 (3.7)</td>
<td>16 (15.0)</td>
</tr>
<tr>
<td>Ventricular fibrillation</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other rhythm ‡</td>
<td>2 (3.7)</td>
<td>0</td>
<td>1 (0.9)</td>
<td>2 (3.7)</td>
</tr>
<tr>
<td>Any bradycardia event§</td>
<td>1 (1.9)</td>
<td>11 (10.9)</td>
<td>7 (6.5)</td>
<td>2 (3.7)</td>
</tr>
<tr>
<td>Any HR &lt;40 bpm on Holter</td>
<td>1 (1.9)</td>
<td>1 (1.9)</td>
<td>4 (3.7)</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>Any hypotension event</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP &lt;90 mm Hg</td>
<td>0</td>
<td>9 (16.7)</td>
<td>6 (5.6)</td>
<td>1 (1.9)</td>
</tr>
</tbody>
</table>

HR=heart rate; SBP=systolic blood pressure.

*Derived from adverse events (AEs), Holter monitoring, and 12-lead electrocardiograms (ECGs). Patients may have experienced >1 event.

†Wide complex beats (≥3 beats) with an HR ≥100 bpm.

‡Other rhythm includes aberrant pair, ventricular pair, and ventricular bigeminus.

§Incidence based on combined analysis of AEs, 12-lead ECGs, including sinus bradycardia (HR <60 bpm), and Holter monitoring.

||Incidence based on combined analysis of AEs and vital signs assessments (SBP <90 mm Hg, SBP decrease from baseline ≥30 mm Hg, diastolic blood pressure decrease ≥15 mm Hg).
FIGURE LEGENDS

Figure 1. Patient disposition. *One patient in the vernakalant group was adjudged by the Clinical Events Committee to be in SR prior to and after treatment. SR=sinus rhythm.

Figure 2. Success rates in the overall AF/AFL population and among patients with AF. AF=atrial fibrillation; AFL=atrial flutter.

Figure 3. Cumulative responder percentage based on time after the start of treatment among patients with atrial fibrillation.

Figure 4. Time course of changes from baseline in HR and QRS, QTcB, and QTcF for patients with AF/AFL given vernakalant compared with patients given placebo. Data (mean±SD) are shown for patients who remained in AF or AFL, excepting Figure 4A, which includes vernakalant-treated patients who demonstrated conversion to SR (wide error bars). HR=heart rate; QTcB=Bazett-corrected QT interval; QTcF=Fridericia-corrected QT interval; AF=atrial fibrillation; AFL=atrial flutter; SR=sinus rhythm.
Figure 1.

AF/AFL Patients

Randomized 2:1 (N=190)

Vernakalant (n=127)
Placebo (n=63)

Not Treated

Vernakalant (n=20)
• Spontaneous SR conversion, n=17
• Withdrawn consent, n=2
• Required use of prohibited medication, n=1

Placebo (n=9)
• Spontaneous SR conversion, n=7
• Investigator decision, n=1
• Ineligible for study, n=1

Discontinued

Vernakalant (n=1)*
• Withdrawn consent, n=1

Vernakalant (n=107)*
Placebo (n=54)

Treated

Vernakalant (n=100)
Placebo (n=50)

Completed Study

Vernakalant (n=106)
Placebo (n=54)

Vernakalant (n=100)
Placebo (n=50)
Figure 3.

Vernakalant

47% responders

Median time to conversion among responders = 12.4 min

Placebo

Time to Conversion, min

Percentage

Circulation Arrhythmia and Electrophysiology

P < .001
Figure 4. C

- Placebo
- Vernakalant

Mean (±SD) QTcB, ms

- $P < .001$
- $P < .001$
- $P = .002$
- $P = .017$

Circulation
Arrhythmia and Electrophysiology

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Infusion 1
Infusion 2

Baseline
10
25
35
50

1.5
2

Minutes

Hours

Time
Figure 4. D

- Placebo
- Vernakalant

Mean (±SD) QTcF, ms

P < .001

Infusion 1

Infusion 2

Baseline

Minutes

Time

300

10

25

35

50

1.5

2

Hours
Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation Following Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial
Peter R. Kowey, Paul Dorian, L. Brent Mitchell, Craig M. Pratt, Denis Roy, Peter J. Schwartz, Jerzy Sadowski, Dorota Sobczyk, Andrzej Bochenek and Egon Toft

_Circ Arrhythm Electrophysiol._ published online October 2, 2009;
_Circulation: Arrhythmia and Electrophysiology_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circep.ahajournals.org/content/early/2009/10/02/CIRCEP.109.870204

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Arrhythmia and Electrophysiology_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Arrhythmia and Electrophysiology_ is online at:
http://circep.ahajournals.org/subscriptions/